REG - Haleon PLC - Director/PDMR Shareholding

HALEONAnnouncement

Today 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260313:nRSM6406Wa&default-theme=true

RNS Number : 6406W  Haleon PLC  13 March 2026

 

Haleon plc: Director/PDMR Shareholding

 

13 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by Persons
Discharging Managerial Responsibilities ("PDMRs").

This notification sets out the details of the grant of Haleon share awards
over Ordinary Shares made to PDMRs under the Haleon Performance Share Plan and
Deferred Annual Bonus Plan.

The Performance Share Plan main awards are subject to performance conditions
over the performance period ending on 31 December 2028. Performance targets
are disclosed in the 2025 Annual Report and 20-F.

All awards were made in line with the principles of Haleon's Directors'
Remuneration Policy and are subject to malus and clawback provisions.

 

 1       Details of the issuer or emission allowance market participant

 a)      Name of the entity                                       Haleon plc

 b)      LEI                                                      549300PSB3WWEODCUP19

 2       Reason for the notification

 a)      Position/status                                          Chief Executive Officer

 b)      Initial notification /Amendment to prior notifications   Initial Notification

 3       Details of the person discharging managerial responsibilities / person closely

       associated ("PCA")

 a)      PDMR/PCA                                                 PDMR

 b)      Name                                                     Brian McNamara

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                (i)       Grant of a conditional award under the Haleon plc Performance

                                                        Share Plan

                                                        (ii)      Grant of a conditional award under the Haleon plc Deferred
                                                                  Annual Bonus Plan
 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                    (i)               Nil               1,639,855
                                                                                    (ii)              Nil               173,825

 d)      Aggregated information

         - Aggregated volume                                      1,813,680

         - Price                                                  Nil

 e)      Date of the transaction                                  12 March 2026

 f)      Place of the transaction                                 Outside a trading venue

 

 1       Details of the issuer or emission allowance market participant

 a)      Name of the entity                                       Haleon plc

 b)      LEI                                                      549300PSB3WWEODCUP19

 2       Reason for the notification

 a)      Position/status                                          Chief Financial Officer

 b)      Initial notification /Amendment to prior notifications   Initial Notification

 3       Details of the person discharging managerial responsibilities / person closely

       associated ("PCA")

 a)      PDMR/PCA                                                 PDMR

 b)      Name                                                     Dawn Allen

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                (i)       Grant of a conditional award under the Haleon plc Performance

                                                        Share Plan

                                                        (ii)      Grant of a conditional award under the Haleon plc Deferred
                                                                  Annual Bonus Plan
 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                    (i)               Nil               712,784
                                                                                    (ii)              Nil               95,513

 d)      Aggregated information

         - Aggregated volume                                      808,297

         - Price                                                  Nil

 e)      Date of the transaction                                  12 March 2026

 f)      Place of the transaction                                 Outside a trading venue

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBSGDXXBBDGLX



            Copyright 2019 Regulatory News Service, all rights reserved